Pcn90 - Cost-Effectiveness and Budget Impact Analysis of Nilotinib for the Second Line Tratment of Chronic Mieloid Leukemia in the Russian Federation
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.172
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV